Intestinal inflammation responds to microbial tissue load independent of pathogen/non-pathogen discrimination.

PloS One
Yvonne WillerDirk Bumann

Abstract

The intestinal immune system mounts inflammatory responses to pathogens but tolerates harmless commensal microbiota. Various mechanisms for pathogen/non-pathogen discrimination have been proposed but their general relevance for inflammation control is unclear. Here, we compared intestinal responses to pathogenic Salmonella and non-pathogenic E. coli. Both microbes entered intestinal Peyer's patches and, surprisingly, induced qualitatively and quantitatively similar initial inflammatory responses revealing a striking discrimination failure. Diverging inflammatory responses only occurred when Salmonella subsequently proliferated and induced escalating neutrophil infiltration, while harmless E. coli was rapidly cleared from the tissue and inflammation resolved. Transient intestinal inflammation induced by harmless E. coli tolerized against subsequent exposure thereby preventing chronic inflammation during repeated exposure. These data revealed a striking failure of the intestinal immune system to discriminate pathogens from harmless microbes based on distinct molecular signatures. Instead, appropriate intestinal responses to gut microbiota might be ensured by immediate inflammatory responses to any rise in microbial tissue loads, ...Continue Reading

References

Apr 16, 1999·Journal of Gastroenterology·K FukushimaS Matsuno
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Aug 29, 2000·American Journal of Physiology. Gastrointestinal and Liver Physiology·H OgawaS Matsuno
Oct 14, 2000·Annual Review of Cell and Developmental Biology·J P Kraehenbuhl, M R Neutra
Dec 23, 2003·Infection and Immunity·Cédric CheminayMichael Hensel
Mar 23, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·David S WeissArturo Zychlinsky
May 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrés Vazquez-TorresFerric C Fang
Jul 16, 2004·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Michael Joseph CoffeyMarc Peters-Golden
Mar 1, 2006·Current Opinion in Allergy and Clinical Immunology·Ian A YangJohn W Holloway
Apr 12, 2006·The Journal of Experimental Medicine·Michael LotzMathias W Hornef
May 23, 2006·Immunity·Rosa Maria Salazar-GonzalezStephen J McSorley
Nov 18, 2006·Nature Immunology·Philippe J Sansonetti
Apr 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anna Rydström, Mary Jo Wick
Oct 24, 2007·Nature Immunology·Eric G Pamer
Feb 2, 2008·Inflammatory Bowel Diseases·Michael Schultz
Oct 20, 2009·European Journal of Immunology·Anna Rydström, Mary Jo Wick
Aug 31, 2010·Inflammatory Bowel Diseases·Elke Cario
Dec 15, 2010·Mucosal Immunology·P J Sansonetti
Jun 23, 2011·PloS One·Christian StelterDirk Bumann

❮ Previous
Next ❯

Citations

Oct 4, 2014·Journal of Cell Communication and Signaling·C SchmidtR Wetzker

❮ Previous
Next ❯

Methods Mentioned

BETA
confocal microscopy
FCS
flow cytometry

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.